Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Better Therapeutics Inc (NQ: BTTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Better Therapeutics Inc < Previous 1 2 3 Next > Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq March 14, 2024 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers March 05, 2024 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) March 04, 2024 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease February 20, 2024 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment February 06, 2024 From Better Therapeutics Inc. Via Business Wire Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone January 17, 2024 From Better Therapeutics Inc. Via Business Wire Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States January 04, 2024 From Better Therapeutics Via Business Wire Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease January 02, 2024 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions November 28, 2023 From Better Therapeutics, Inc. Via Business Wire Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award November 14, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates November 09, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023 November 08, 2023 From Better Therapeutics Via Business Wire Better Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual Conference October 26, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances October 05, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes October 16, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes September 28, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes October 11, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates August 09, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023 August 02, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share July 25, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Receives FDA Authorization for AspyreRx™ to Treat Adults with Type 2 Diabetes July 10, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Announces Upcoming Poster Presentation at EASL Congress 2023 in Vienna, Austria June 16, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates May 11, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 May 04, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Announces $6.5MM Private Placement April 06, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates March 30, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 30, 2023 March 23, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics to Participate in Two Upcoming Investor Conferences February 09, 2023 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results December 08, 2022 From Better Therapeutics, Inc. Via Business Wire Better Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 02, 2022 From Better Therapeutics, Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
